198 related articles for article (PubMed ID: 23948854)
1. Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study.
Yang H; Li H; Wang Z; Gao J; Guo Y
Urol Int; 2013; 91(4):456-61. PubMed ID: 23948854
[TBL] [Abstract][Full Text] [Related]
2. [Value of detection of preoperative urinary soluble Fas expression in predicting the recurrence of non-muscle invasive bladder cancer].
Yang H; Guo Y; Wang Z; Wang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Jan; 41(1):24-9. PubMed ID: 26819421
[TBL] [Abstract][Full Text] [Related]
3. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
6. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.
Ajili F; Kacem M; Tounsi H; Darouiche A; Enayfer E; Chebi M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Oct; 36(5):336-42. PubMed ID: 22574784
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
10. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
12. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
Yun SJ; Jo SW; Ha YS; Lee OJ; Kim WT; Kim YJ; Lee SC; Kim WJ
Urol Oncol; 2012; 30(6):893-9. PubMed ID: 21396842
[TBL] [Abstract][Full Text] [Related]
13. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
14. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
[TBL] [Abstract][Full Text] [Related]
15. Urine tenascin‑C is an independent risk factor for bladder cancer patients.
Guan Z; Zeng J; Wang Z; Xie H; Lv C; Ma Z; Xu S; Wang X; He D; Li L
Mol Med Rep; 2014 Mar; 9(3):961-6. PubMed ID: 24366195
[TBL] [Abstract][Full Text] [Related]
16. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
[TBL] [Abstract][Full Text] [Related]
17. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
18. Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer.
Azuma T; Nagase Y; Oshi M
Clin Genitourin Cancer; 2013 Sep; 11(3):331-6. PubMed ID: 23664207
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?
Gontero P; Gillo A; Fiorito C; Oderda M; Pacchioni D; Casetta G; Peraldo F; Zitella A; Tizzani A; Ricceri F
Urol Int; 2014; 92(2):136-42. PubMed ID: 24080613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
